Introduction

Enterobiasis (also known as pinworm infection) is caused by the helminth (parasitic worm) Enterobius vermicularis. It is among the most frequent worm infections in humans, particularly children, because of its easy transmission (faecal‑oral route).

It shows symptoms, such as perianal itching (aggravated at night), sleep disturbance, irritability, and occasionally abdominal pain. Treatment is not only necessary for symptom relief, but also to prevent reinfection, break transmission (particularly in households and schools), and decrease morbidity.

Worldwide, enterobiasis is an important public health problem where crowded living conditions, poor sanitation, or poor hygiene practices exist. Although the disease is generally not life-threatening, its high prevalence and frequency of relapse make treatment valuable.

Overview of anthelmintic drugs used for enterobiasis

The main anthelmintic (anti‑worm) drugs used for treating enterobiasis include:

• Mebendazole
• Albendazole
• Pyrantel pamoate

These are recommended by public health authorities, including the U.S. Centres for Disease Control & Prevention (CDC), and described in pharmacology monographs.¹

Mechanisms of action

• Mebendazole binds to β‑tubulin in helminths, preventing microtubule polymerisation. This inhibits glucose uptake in the parasite, interferes with energy metabolism, reproduction (egg development), and results in its death. The drug is minimally systemically absorbed, which localises its effect in the gut and minimises systemic side effects²
• Albendazole is a benzimidazole with a comparable mechanism (inhibits tubulin polymerisation). It has somewhat greater activity because of better absorption and bioconversion within the body^{3, 4}
• Pyrantel pamoate exerts its effect by inducing neuromuscular blockade of the parasite: it induces spastic paralysis of the worm, which is then eliminated by gut motility. It tends to be fast-acting and less is absorbed systemically⁵

Efficacy of current therapies

Cure rates and normal dosing

Albendazole dose (400 mg) alone has been evaluated in several trials to yield 100% cure rates for E. vermicularis in most situations. A multicenter trial involving 480 patients with various nematodes (including pinworm infection) treated with albendazole cured all cases of enterobiasis after a single dose.⁶ 

In Pakistan, a study in 6‑15-year-old children revealed that albendazole attained ~82.4% efficacy against enterobiasis^.7

Mebendazole, a single dose of 100 mg (with repeat after 2 weeks if required), is commonly used, but reinfection is a problem. The U.S. CDC advocates for a repeat dose in 2 weeks to kill any eggs.¹

Pyrantel pamoate is also effective, particularly in a single dose, and is used as an alternative when benzimidazoles are not available or less acceptable.⁵

Factors that modify efficacy

1. Reinfection: Since E. vermicularis eggs can stay in bedding, clothing, the environment, or be transmitted between members of the household, reinfection occurs and lowers apparent efficacy unless follow-up is appropriately timed
2. Compliance with dosing: Missing doses, failing to treat all household members, or failing to repeat the dose when necessary all decrease treatment success
3. Environmental and hygiene control: Handwashing, washing bed linens, cleaning surfaces, clipping nails, etc. Without them, even very active drugs won't prevent infection recurrence

Resistance to anthelmintic drugs

What is currently known?

Compared with many other parasitic helminths (hookworms, whipworms, etc.), Enterobius vermicularis has not yet demonstrated widespread confirmed resistance in human populations. The majority of conventional treatments are still effective. There are, however, isolated reports and trials reporting reduced efficacy or treatment failure in certain environments.

Evidence and studies

In Egypt, a clinical trial compared albendazole alone vs albendazole‑flubendazole combination in children with recurrent/resistant pinworm infection. The combination achieved an 83.1% cure rate vs 55.4% with albendazole alone in those considered resistant. This suggests that in some “resistant” cases, alternative or combination regimens might be required.⁸

A Japanese case report summarised a patient who had been treated repeatedly with pyrantel pamoate over the years but did not eliminate E. vermicularis eggs; subsequently treated with albendazole thrice, which yielded lasting negative results for at least one year. Although a single case, it raises potential diminished sensitivity or other non‑drug failure factors (such as reinfection or misdiagnosis).⁹

Potential mechanisms of resistance

β‑tubulin gene mutations in worms have been shown to make other helminths resistant to benzimidazole class drugs. This is probably the route to decreased sensitivity in Enterobius as well. Evidence from other nematodes indicates that drug pressure (repeated use, mass drug administration) can select for such mutations.² Overuse / inappropriate dosing (e.g., failure to repeat treatment, failure to treat family contacts) may also enhance selection pressure.

Alternative and supportive measures

Since drugs work well but compliance and reinfection are major problems, supportive measures are needed:

• Treat all the contacts in the household at the same time to cut down on reinfection cycles
• Practice hygiene: wash with soap, particularly after using the toilet and before eating; have fingernails trimmed and clean
• Decontamination of the environment: bedclothes, underwear, and pyjamas should be washed regularly in hot water; surfaces disinfected 
• Repeated dosing: usually a second dose 2 weeks after the initial dose to catch worms that developed or eggs that hatched after the initial treatment. This is included in most guidelines.¹

Prevention and control measures

• Public Health Guidelines recommend infection control in schools and communities: hygiene education, availability of sanitation, and regular treatment in high‑prevalence facilities
• WHO recommendations for preventive chemotherapy (mass or large-scale deworming) are more soil-transmitted helminth (Ascaris, hookworm, Trichuris) specific, but many of the principles are still applicable: periodic dosing, drug efficacy monitoring, and compliance check¹⁰
• Monitoring for possible drug resistance: research to track cure rates, egg reduction rates, and possibly molecular analysis of parasite populations where failure is noted

Summary

Enterobius vermicularis (pinworm) infestation is a prevalent parasitic infection, most often in children; although not generally dangerous, it has a significant effect on quality of life because of symptoms such as perianal pruritus and sleep interference. Routine anthelmintic treatments, albendazole, mebendazole, and pyrantel pamoate, are usually highly effective, with cure rates of between 90–100% under the best circumstances^. Nevertheless, the success of the treatment is frequently jeopardised by elements of reinfection from environmental contamination or untreated contacts, inadequate compliance, and perhaps waning drug efficacy in certain environments. While definite resistance has occurred rarely, new clinical experiences and trials, including the Egyptian trial on albendazole-flubendazole combination therapy, indicate that alternative regimens in recurrent or persistent cases are warranted. Most importantly, the pharmacological therapy is complemented by strict hygiene precautions, environmental disinfection, treatment of all close contacts, and repeated dosing. Proper diagnosis (e.g., through the tape test), dosing, and compliance with prophylactic measures are essential to the success of the therapy and avoidance of re-infection. Clinical follow-up, resistance monitoring, and molecular techniques are needed to ensure control and to inform future therapeutic options.

FAQs

Q1: How is enterobiasis diagnosed reliably?

Answer - Typically, through the tape test (applying adhesive tape to perianal skin in the morning to pick up eggs). Stool examination is less sensitive for pinworms. Clinical presentation (night‑time pruritus) can be quite helpful, particularly in children.

Q2: How long until treatment works?

Answer - After one dose of an effective drug, the symptoms could clear rapidly (in a few days). But eggs that have already been laid could remain, and larvae could hatch from these after the first dose; so repeated doses (usually after ~2 weeks) are advised.

Q3: What if one drug fails?

Answer - 

1. Reinfection or exposure must be minimised (hygiene, environmental decontamination)
2. Consider repeating the same drug (with correct dosing) if adherence was an issue
3. Use an alternative drug (for example, if pyrantel fails, try albendazole or mebendazole)
4. In some reported resistant cases, combination therapy (albendazole + flubendazole) showed better results

Q4: Are there major side effects of these medicines?

Answer - Usually, these drugs are well‑tolerated. Rarely are systemic side effects seen, particularly as absorption is usually low (with mebendazole and pyrantel). The safety of albendazole has been reported for several years.

Q5: What about pregnant women or special populations?

Answer - Some medications are given during the first trimester of pregnancy, but with a warning. Besides, young children need particular dose adjustments. One must consider local/national guidelines.